Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS signs large-molecule licensing agreement with Ambrx

Executive Summary

Ambrx Inc. (protein therapeutics and antibody-drug conjugates) has licensed Bristol-Myers Squibb Co. exclusive global rights to research, develop, and market modified forms of fibroblast growth Factor 21 (FGF-21) for Type II diabetes, and relaxin for heart failure, both currently in preclinical. NOTE: The FGF-21 therapeutic, also known as BMS986036, is also being tested in liver fat, liver injury, and fibrosis in nonalcoholic steatohepatitis patients.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies